Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Clin Pharmacol Ther. 2017 Nov;102(5):765-776. doi: 10.1002/cpt.787. Epub 2017 Sep 7.

Abstract

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

Publication types

  • Review

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Monitoring / methods
  • Drug Monitoring / standards*
  • Humans
  • Medical Oncology / methods
  • Medical Oncology / standards*
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Practice Guidelines as Topic / standards*
  • Prospective Studies
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects

Substances

  • Protein Kinase Inhibitors